Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06396533 · ClinicalTrials.gov registry record
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
A clinical trial of Urothelial Carcinoma and Muscle Invasive Bladder Urothelial Carcinoma, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- 92
- Enrollment target
- 2
- Study locations
NCT06396533 is a study of Urothelial Carcinoma and Muscle Invasive Bladder Urothelial Carcinoma that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 92 participants, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06396533, a study of Urothelial Carcinoma and Muscle Invasive Bladder Urothelial Carcinoma, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- 92 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy. Patients who are planned for cystectomy due to bladder cancer will be considered for enrollment based on inclusion and exclusion criteria.
Conditions Studied
Study Locations (2)
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2029-02-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06396533
The ClinicalTrials.gov registry entry for NCT06396533 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (61% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT06396533 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Nebraska, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06396533 about?
NCT06396533 is a clinical study titled "Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)". This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy. Patients who are planned fo...
What is the current status of trial NCT06396533?
This trial is currently recruiting. The enrollment target is 92 participants. The study started on 2024-08-13. Estimated completion is 2029-02-23.
What conditions does trial NCT06396533 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma.
Who is sponsoring clinical trial NCT06396533?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06396533 being conducted?
This trial has 2 study locations across Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Explore more on PlainTrial
Urothelial Carcinoma
All registered trials for this condition
Muscle Invasive Bladder Urothelial Carcinoma
All registered trials for this condition
Nebraska
All trials with a study site in Nebraska
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.